New Jersey compounding pharmacy recalls all products, fearing mold contamination
Med Prep Consulting, Inc., a compounding pharmacy in Tinton Falls, NJ, is voluntarily recalling all lots of compounded products from its facility for fear of mold contamination, according to an FDA press release.
Med Prep Consulting, Inc., a compounding pharmacy in Tinton Falls, N.J., is voluntarily recalling all lots of compounded products from its facility for fear of mold contamination, according to an FDA press release.
"The level of recall is to the user, that is, regional hospital pharmacies and related departments, and physician’s office practices," the statement said. "The recall resulted from the pharmacy being notified by a Connecticut hospital, that it observed visible particulate contaminants in 50 mL bags of magnesium sulfate 2GM in dextrose 5% in water, 50 mL for injection intravenous solution confirmed to be mold."
The lots were "unique and distinct" and only dispensed to the Connecticut Hospital. As of March 17, five contaminated bags were discovered, but no injuries or illnesses had been reported.
"Administration of an intravenous product found to be contaminated with mold, could result in a fatal infection in a broad array of patients," the release stated.
FDA recently released the results of the inspection observations of 15 pharmacies.
Although 2 of the 15 pharmacies were in New Jersey, Med Prep Consulting was not one of them.
Med Prep offers sterile compounding and is a specialty intravenous pharmacy, according to its website.
All facilities that received Med Prep compounded products were notified and have been instructed to send the medication back to the pharmacy.
This recall comes just as the news surrounding the nationwide meningitis outbreak in October is winding down. The outbreak stemmed from contaminated medication produced by the New England Compounding Center.
Check these out, too…
"60 Minutes'" coverage on meningitis tragedy doesn't tell complete story, NCPA says
Debate surfaces over preferred treatments for fungal meningitis outbreak
Details illuminate start of fungal meningitis outbreak
Did FDA have authority to shut down NECC before meningitis outbreak?
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
CVS Caremark Makes Changes in Diabetes Coverage for 2025
Published: November 25th 2024 | Updated: November 25th 2024CVS Caremark has removed several diabetes drugs favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.
Read More
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
